Multistage Delivery System for Targeted Therapeutic Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic and imaging agents face challenges in selectively targeting diseased cells and tissues with minimal collateral damage due to inadequate delivery systems, leading to suboptimal efficacy and increased side effects.
Innovation Solution
A multistage delivery system comprising micro or nanoparticles with a body, surface, and reservoir, where smaller active agent particles are loaded inside the larger particles, equipped with targeting moieties and permeation enhancers to facilitate selective localization and release at target sites, overcoming biological barriers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional delivery systems are used to administer therapeutic agents, then the agents can be delivered to target sites, but they fail to selectively reach desired targets and cause collateral damage to healthy tissues
Solution Approach 1:
The patent employs a multistage delivery system where smaller second-stage particles containing active agents are nested inside larger first-stage particles. The first-stage particles serve as outer carriers that protect and transport the second-stage particles through biological barriers, while the second-stage particles are released at the target site for selective action on diseased cells, thereby improving targeting reliability and reducing collateral damage.
Solution Approach 2:
The delivery system is segmented into multiple functional stages: first-stage particles provide protection and transport capabilities, while second-stage particles contain the actual therapeutic or imaging agents. This segmentation allows each stage to be optimized for its specific function, with the outer layer protecting against premature release and the inner layer ensuring selective delivery to target sites.
2Reliability
If single-stage delivery particles are used, then the structure is simple, but they cannot overcome multiple biological barriers and achieve preferential delivery
Solution Approach 1:
The nested multistage structure enables the delivery system to overcome multiple biological barriers sequentially. The first-stage outer particles are designed to traverse initial barriers such as the gastrointestinal tract or bloodstream, while the second-stage inner particles are released at the target site to overcome final cellular barriers, achieving preferential delivery through a complex but functional multilayer architecture.
Solution Approach 2:
The first-stage particles serve multiple functions: protecting the second-stage particles during transport, facilitating traversal through initial biological barriers, and enabling controlled release at the target site. This multi-functionality justifies the increased structural complexity by consolidating multiple delivery challenges into a single integrated system.
3Reliability
If high concentrations of active agents are administered to ensure target coverage, then therapeutic efficacy is maximized, but side effects and toxicity increase
Solution Approach 1:
The nested structure allows high concentrations of active agents to be encapsulated within second-stage particles protected by first-stage carriers. This protection prevents premature release and systemic toxicity, while ensuring concentrated delivery precisely at the target site, thereby maintaining high therapeutic efficacy without proportionally increasing side effects.
Solution Approach 2:
The delivery system concentrates the active agents locally at the target site through selective release of second-stage particles, rather than distributing them systemically. This local concentration achieves high therapeutic efficacy at the disease site while minimizing exposure and toxicity to healthy tissues throughout the rest of the body.
Data Source
AI summary
Multistage delivery vehicles are disclosed which include a first stage particle and a second stage particle. The first stage particle is a micro or nanoparticle that contains the second stage particle. The second stage particle includes an active agent, such as a therapeutic agent or an imaging agent. The multistage delivery vehicle allows sequential overcoming or bypassing of biological barriers. The multistage delivery vehicle is administered as a part of a composition that includes a plurality of the vehicles. Methods of making the multistage delivery vehicles are also provided.